Strong interest in Modus TO programme
Modus Therapeutics strengthens its financial position and focuses on the Phase IIa study with sevuparin. KDventures subscribed for its share in the TO2 warrant programme.
Published
Investor News
Several portfolio companies are approaching crucial data readings and potential deals
Comment by Viktor Drvota
Don’t miss the annual report for 2025
2025 was filled with progress in clinical development and strategic collaborations across our portfolio companies. During the latter part of the year, we laid the groundwork for the financing round that...
Published
Rights issue completed
KDventures reported the outcome of the rights issue after the subscription period ended on 27 January 2026.
Published
Viktor Drvota at Redeye
Watch KDventure's CEO Victor Drvota present the company's investment strategy and answer questions.
Published
AnaCardio extends IP protection in the USA
Increases the commercial potential of the heart failure drug candidate.
Published
Organon discontinues development
Halts development of the drug candidate included in the acquisition of Forendo in 2021.
Published
Dilafor signs agreement with Exeltis
Global pharmaceutical company funds Phase 3 studies with tafoxiparin.
Published
Reports and presentations
Here you can find annual reports, interim reports, year-end reports and presentations from capital markets days.